

# First Quarter Figures 2022

Analyst Presentation  
15 June 2022

15 June 2022

what is precious to you?



# Disclaimer

This presentation contains certain statements that are neither reported financial results nor other historical information.

This presentation also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements.

Many of these risks and uncertainties relate to factors that are beyond Clariant's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators, and other risk factors, such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company's ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social, and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency

fluctuations, inflation, and consumer confidence, on a global, regional, or national basis.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document.

Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.

# First Quarter 2022




# Markedly Stronger Sales Growth in Q1... ...16 % Price Contribution to Top-line Growth of Specialty Portfolio


## 1 Q1 sales (continuing operations) up + 30 % in LC<sup>1</sup>

- Sales driven by **strong growth** in Care Chemicals, especially Aviation, Coatings, Crop Solutions, and Personal Care as well as Natural Resources, especially Additives
- Demand remained strong across all businesses and regions
- **+14 %** volume increase (+10 % organic<sup>2, 3</sup>) / **+16 %** price contribution
- Continued cost inflation again largely offset by pricing measures
- Organic growth well above pre-COVID-19 level
- Positive sales contribution<sup>3</sup> from CISC and Beraca – integration almost completed

Quarterly pricing  
year-on-year



Sales in CHF m




<sup>1</sup> in local currency; <sup>2</sup> core volume growth of 10 %, excluding consolidation of Clariant IGL Specialty Chemicals Private Limited (CISC) and Beraca in Care Chemicals; <sup>3</sup> sales of c. CHF 42 million in Q1 2022



# Strong Growth in Q1... ...Delivered Further Profitability Improvement

## 2 Q1 EBITDA margin increased to 17.4 %

- Q1 EBITDA improved by **10 basis points**, driven by **operating leverage from higher sales, cost savings, and pricing measures**
- Pricing raised to **+ 16 %** to diminish the raw material, energy, and logistics cost inflation
- Accelerated inflationary environment resulted in:
  - Energy cost increasing by c. 38 % (mainly in Europe)
  - Raw material cost continuing to increase by c. 37 %
  - Logistic cost increasing by c. 17 %



<sup>1</sup> restated



# Executed Strategic Priorities in Q1

## 3 Completion of key growth projects

### Commissioning of the sunliquid® production plant in Podari, Romania

- Industrial scale of sunliquid® process for 2G cellulosic bioethanol production
- Successful technical ramp-up in Q1 2022
- All required permissions received in Q2 2022
- Sales ramp-up in H2 2022

### Commissioning of CATOFIN® plant in Jiaxing, China

- Local production capacity for CATOFIN® propane dehydrogenation (PDH) catalyst
- Ramp-up and chemical commissioning concluded in Q1 2022
- First sales contribution expected in Q2 2022

## 4 Divestments closed

### Pigments and Scientific Design divestments closed

- Pigments divestment closed on 3 January 2022, resulting in net cash inflow of ~ CHF 615 million<sup>1</sup> and a provisional pretax gain on disposal of CHF 168 million
- Divestment of 50 % stake in Scientific Design closed on 14 April 2022, resulting in Clariant net cash inflow of ~ USD 139 million<sup>1</sup> in Q2 2022

## 5 Focus on savings

### Performance programs on track

- Efficiency programs contributed ~ CHF 4 million cost savings in Q1
- Expected FY 2022 EBITDA contribution of ~ CHF 20 million
- On track to achieve total cost savings (efficiency and rightsizing programs) of ~ CHF 110 million by 2025

<sup>1</sup> before tax and transaction costs

# Upcoming Annual General Meeting and FY 2022 Outlook

## 6 AGM 2022 on 24 June 2022

- Proposed reelection of Günter von Au as Chairman
- Proposed three new members to the Board of Directors nominated by SABIC
- Recommendation of a regular distribution of CHF 0.40 per share through capital reduction by way of par value reduction
- Proposed KPMG AG as statutory auditor for 2022

## 7 FY 2022 Group guidance confirmed

- Full Year 2022 expectations:
  - Strong LC<sup>1</sup> sales growth driven by particularly strong H1 2022, benefiting from solid end-markets fundamentals
  - Aim to improve y-o-y EBITDA margin level
- Current high uncertainty level as a result of geopolitical conflicts, suspension of business in Russia, and resurgence of COVID-19 in China expected to continue to impact global economic growth and demand in H2 2022


<sup>1</sup> in local currency



# First Quarter 2022 – Group<sup>1</sup> Overview 1/2

<i>in CHF m</i>	Q1 2022	Q1 2021	% CHF	% LC <sup>2</sup>
Sales	1 262	1 002	+ 26	+ 30
EBITDA	220	173 <sup>4</sup>	+ 27	
EBITDA margin	17.4 %	17.3 %		
EBITDA b.e.i. <sup>3</sup>	238	178 <sup>4</sup>	+ 34	
EBITDA b.e.i. <sup>3</sup> margin	18.9 %	17.8 %		
<b>Sales Bridge</b> >	<b>Sales</b> + 26 %	<b>Price</b> + 16 %	<b>Volume</b> + 14 %	<b>Currency</b> - 4 %

## Business Area composition<sup>1</sup> (in %)



### Accelerating strong sales growth dynamic

- **+ 30 % LC<sup>2</sup> growth** due to both **higher volumes** and **increased pricing in Q1**
- **Strong Care Chemicals** (Aviation, Coatings, Crop Solutions, Personal Care) **and Natural Resources** (Additives); **Catalysis** slightly lower
- Consolidation of CISC and Beraca in Care Chemicals represented 4 % LC<sup>2</sup> growth
- All regions contributed to positive development
- Slightly negative currency impact across the Group

### EBITDA margin up by 10 basis points

- **Absolute EBITDA increased by 27 %** versus prior year, and the reported margin rose to 17.4 %
- **Operating leverage** from very **strong volume growth** and **accelerated pricing measures**, which partially offset ongoing cost inflation for raw materials, energy, and freights
- Execution of the **efficiency programs<sup>5</sup>** and continued **cost discipline**

<sup>1</sup> continuing operations; <sup>2</sup> local currency; <sup>3</sup> before exceptional items; <sup>4</sup> restated; <sup>5</sup> efficiency programs contributed c. CHF 4 m to continuing operations




# First Quarter 2022 – Group<sup>1</sup> Overview 2/2

## Geographic split

**Sales CHF 1 262 m**

in CHF m, % in local currency

● Emerging markets ● Mature markets



- **Europe** with strong sales growth in Care Chemicals (both Consumer Care and Industrial Applications) and notable expansion in Natural Resources (all Business Units), weaker Catalysis sales
- Growth in **Asia-Pacific** driven by continued high demand with positive contributions from Care Chemicals (including CISC consolidation) and Natural Resources (Additives, OMS). **China** with a continued robust increase in Catalysis (CATOFIN<sup>®</sup>) and in Additives
- Strong growth in **North America** attributable to all Business Areas, especially Catalysis
- Sales growth in **Latin America** across all Business Areas, in particular in Care Chemicals and Natural Resources (all Business Units)
- **Middle East & Africa** with strong growth in Care Chemicals and Natural Resources

<sup>1</sup> continuing operations



# First Quarter 2022 – Care Chemicals

<i>in CHF m</i>	<b>Q1 2022</b>	Q1 2021	% CHF	% LC <sup>1</sup>
<b>Sales</b>	<b>566</b>	404	+ 40	+ 44
<b>EBITDA</b>	<b>130</b>	80 <sup>3</sup>	+ 63	
<b>EBITDA margin</b>	<b>23.0 %</b>	19.8 %		
EBITDA b.e.i. <sup>2</sup>	<b>132</b>	80 <sup>3</sup>	+ 65	
EBITDA b.e.i. <sup>2</sup> margin	<b>23.3 %</b>	19.8 %		
<b>Sales Bridge</b> >	<b>Sales</b> + 40 %	<b>Price</b> + 23 %	<b>Volume</b> + 21 %	<b>Currency</b> - 4 %

## Market Dynamics

- Global industrial demand remained strong
- Increased consumer market dynamics
- Continued raw material cost inflation paired with ongoing supply chain uncertainties

## Particularly resounding + 44 % LC<sup>1, 4</sup> sales growth across all key business lines, underpinned by higher prices and volumes

- **Consumer Care** sales increased in a double-digit range in all three businesses: Personal Care, Home Care, with expansion in Crop Solutions again in the lead
- **Industrial Applications** organic sales rose at a double-digit rate, resulting from continued end-market strength. All key Business Lines contributed to this growth, especially Aviation and Coatings
- **All regions** reflected significant growth; positive development in Asia boosted by the consolidation of CISC

## EBITDA margin improvement of 320 basis points

- Absolute **EBITDA up by a resounding 63 %**, **EBITDA margin 23.0 %**. Continued high operating leverage from growth. Active price management counterbalanced raw material cost headwinds, supply chain constraints as well as energy and logistics cost increases

<sup>1</sup> local currency; <sup>2</sup> before exceptional items; <sup>3</sup> restated; <sup>4</sup> 30 % sales growth in local currency, excluding c. CHF 42 million in Q1 2022 related to the consolidation of Clariant IGL Specialty Chemicals Private Limited (CISC) and Beraca

# First Quarter 2022 – Catalysis

<i>in CHF m</i>	<b>Q1 2022</b>	Q1 2021	% CHF	% LC <sup>1</sup>
<b>Sales</b>	<b>185</b>	193	- 4	- 1
<b>EBITDA</b>	<b>14</b>	38 <sup>3</sup>	- 63	
<b>EBITDA margin</b>	<b>7.6 %</b>	19.7 %		
EBITDA b.e.i. <sup>2</sup>	<b>14</b>	38 <sup>3</sup>	- 63	
EBITDA b.e.i. <sup>2</sup> margin	<b>7.6 %</b>	19.7 %		
<b>Sales Bridge</b> >	<b>Sales</b> - 4 %	<b>Price</b> + 3 %	<b>Volume</b> - 4 %	<b>Currency</b> - 3 %

## Market Dynamics

- Continued demand for more sustainable solutions and continued investments in capacity
- Ongoing demand in C3<sup>4</sup> value chain; Syngas and emission-control demand accelerated
- Continued challenges in supply chains and unprecedented freight cost levels

### Slightly lower LC<sup>1</sup> sales as higher prices partially compensated for lower volumes

- Strong sales expansion in **Specialty Catalysts**, largely counterbalanced weaker **Syngas** and **Petrochemicals** sales
- Sales expansion was strong in **Asia** and **North America**, in part due to high demand seen in **China**. **Europe** reported lower sales in Q1, reflecting the normal project nature of the business

### Lower EBITDA margin due to inflation, product mix, continued logistics challenges, and project cost

- **EBITDA margin 7.6 %** due to: **1) vast and fast inflationary pressure** amplified by long project lead times; this was addressed by adjusting relevant pricing, which should generate positive impact in H2 2022; **2) less favorable product mix** despite record-high order book, which signifies a marked recovery in H2 2022; **3) continued logistics challenges** resulted in delayed deliveries; **4) project cost** related to new CATOFIN<sup>®</sup> production site in China and sunliquid<sup>®</sup> production plant in Romania
- Record-high order book for H2 2022 with strong fundamentals and additional CATOFIN<sup>®</sup> capacity in China

<sup>1</sup> local currency; <sup>2</sup> before exceptional items; <sup>3</sup> restated; <sup>4</sup> propylene



# First Quarter 2022 – Natural Resources

<i>in CHF m</i>	<b>Q1 2022</b>	Q1 2021	% CHF	% LC <sup>1</sup>
<b>Sales</b>	<b>511</b>	405	+ 26	+ 31
<b>EBITDA</b>	<b>102</b>	69 <sup>3</sup>	+ 48	
<b>EBITDA margin</b>	<b>20.0 %</b>	17.0 %		
EBITDA b.e.i. <sup>2</sup>	<b>102</b>	70 <sup>3</sup>	+ 46	
EBITDA b.e.i. <sup>2</sup> margin	<b>20.0 %</b>	17.3 %		
<b>Sales Bridge</b> >	<b>Sales</b> + 26 %	<b>Price</b> + 15 %	<b>Volume</b> + 16 %	<b>Currency</b> - 5 %

## Market Dynamics

- Ongoing strong demand in global industrial sector, i.e., electrical and electronics (E&E), construction, and automotive
- Continued raw material, energy, and freight cost inflation with supply chain challenges
- Strong demand for sustainable solutions, i.e., in Additives

## Notable + 31 % LC<sup>1</sup> sales growth, expansion across all Business Units and regions

- **Oil and Mining Services (OMS)** sales grew markedly, in a high-twenties percentage range, continuing the sequential quarter-on-quarter improvement, albeit against a weak comparison basis in Oil Services in particular. Growth was strong in all three businesses
- **Functional Minerals (FM)** sales rose in a low-teen range, supported by expansion in almost all Business Lines (especially Purification and Cargo & Device Protection). Foundry sales increased at a mid-single-digit rate, slightly exceeding absolute Q1 2019 levels (pre-COVID-19)
- **Additives (ADD)** sales expansion outperformed that of the other Business Units due to extraordinarily strong underlying demand in all regions and in all main end markets, such as electrical and electronics as well as the automotive (e-mobility) and construction sectors

## EBITDA margin improvement of 300 basis points, driven by Additives

- Absolute **EBITDA with a substantial 48 % improvement, EBITDA margin 20.0 % driven by Additives**. Strong leverage from growth and pricing measures successfully diminished the impact of higher raw material cost, curtailed material availability, and logistics challenges

<sup>1</sup> local currency; <sup>2</sup> before exceptional items; <sup>3</sup> restated

# Outlook 2022



# Outlook Q2 2022

## Care Chemicals

### Q2 2022 Outlook:

- Strong y-o-y sales growth in LC,<sup>1</sup> driven by continued pricing measures and CISC and Beraca contributions, compensating for a normalizing sales growth pattern; sequentially lower (seasonality)
- EBITDA margin level improving y-o-y, but sequentially broadly in line, despite seasonality, continued raw material cost inflation; higher logistics, labor, and energy cost

## Catalysis

### Q2 2022 Outlook:

- Sales slightly below prior year's level and moderate sequential growth in LC<sup>1</sup>, partly due to suspension of business with Russia
- EBITDA margin below previous year's level, sequentially only slight improvement in light of continued inflationary environment and continued project effects

## Natural Resources

### Q2 2022 Outlook:

- Strong y-o-y sales growth in LC,<sup>1</sup> sequentially lower (seasonality), supported by pricing measures in a normalizing growth environment and impacted by the suspension of Russia business
- EBITDA margin on similar level y-o-y, but sequentially lower; impacted by the lagging effect from raw material and labor cost inflation as well as continued high logistics and energy cost

## Group

### Q2 2022 Outlook:

- Strong LC<sup>1</sup> sales growth y-o-y; sequentially moderate decline (positive seasonality effect in Q1)
- Expecting to improve y-o-y EBITDA margin levels, sequentially target to be broadly in line with Q1 2022 margin level, especially via volume growth, continuing pricing actions, and cost discipline

<sup>1</sup> local currency

# Full Year Outlook 2022 Confirmed – Strong Sales Growth; Expecting to Improve EBITDA Margin Levels

## External Factors

- Geopolitical conflict impacting global economic growth and consumer demand in H2 in particular
- High inflationary environment to persist in 2022
- Continued risk of rising raw material, energy, and logistics cost/constraints as well as supply chain uncertainties
- Resurgence of COVID-19 in China

## FY 2022 Group

- **Strong sales growth** in LC<sup>1</sup> based on strong H1, benefiting from solid end-markets fundamentals
- Expecting to **improve** year-on-year EBITDA margin levels

Based on the assumption of strong H1 and high uncertainty/risks in the economic environment in H2

## Internal Factors

- Continued pricing measures to close gap from lagging
- Ongoing execution of performance programs and cost discipline
- Innovation-driven specialty portfolio
- Ramp-up of growth investments (CATOFIN®, sunliquid®) and contribution from bolt-ons CISC, Beraca, Attapulgitite (post closing)
- Suspension of business with Russia

**Continued profitable growth and disciplined execution of strategic growth investments towards confirmed 2025 financial targets:  
Profitable growth (4 – 6 % CAGR), Group EBITDA margin between 19 – 21 %, and a free cash flow conversion of around 40 %**

# Backup Slides

## First Quarter Figures 2022





## First Quarter 2022 – Sales and EBITDA by Business Area

	Sales to third parties			EBITDA <sup>2</sup>		
<i>in CHF m</i>	2022	2021	% LC <sup>1</sup>	2022	2021	% CHF
<b>Care Chemicals</b>	<b>566</b>	<b>404</b>	+ 44 %	<b>130</b>	<b>80</b>	+ 63 %
<i>margin</i>				23.0 %	19.8 %	
<b>Catalysis</b>	<b>185</b>	<b>193</b>	- 1 %	<b>14</b>	<b>38</b>	- 63 %
<i>margin</i>				7.6 %	19.7 %	
<b>Natural Resources</b>	<b>511</b>	<b>405</b>	+ 31 %	<b>102</b>	<b>69</b>	+ 48 %
<i>margin</i>				20.0 %	17.0 %	
<b>Business Areas Total</b>	<b>1 262</b>	<b>1 002</b>	+ 30 %	<b>246</b>	<b>187</b>	
Corporate	–	–		- 26	- 14	
<b>Total Continuing Operations</b>	<b>1 262</b>	<b>1 002</b>	+ 30 %	<b>220</b>	<b>173</b>	+ 27 %
<i>margin</i>				17.4 %	17.3 %	
Discontinued	<b>0</b>	<b>216</b>	<i>n.m.</i>	<b>160</b>	<b>24</b>	<i>n.m.</i>
<b>Total Group</b>	<b>1 262</b>	<b>1 218</b>	<i>n.m.</i>	<b>380</b>	<b>197</b>	<i>n.m.</i>

<sup>1</sup> in local currency; <sup>2</sup> restated, EBITDA before exceptional items Q1 2022 (Q1 2021): Group CHF 238 m / 18.9 % (CHF 178 m / 17.8 %), Care Chemicals CHF 132 m / 23.3 % (CHF 80 m / 19.8 %), Catalysis CHF 14 m / 7.6 % (CHF 38 m / 19.7 %), Natural Resources CHF 102 m / 20.0 % (CHF 70 m / 17.3 %), Discontinued Operations CHF 0 m (CHF 29 m / 13.4 %)

# Add Value with Sustainability – Enabling a Sustainable Future

With people passionate about changing the world, leading-edge operations, and innovative solutions



## Environmental progress

- **Stop climate change** with SBTi-conforming<sup>1</sup> targets:
  - 40 % CO<sub>2</sub> for scope 1 & 2
  - 14 % for scope 3 by 2030<sup>2</sup> and growing handprint
- **Minimize environmental footprint** with updated targets on water, wastewater, waste, and NOx



## Social progress

- **Leading in personal safety** – low Lost-Time Accident Rate/DART (Days Away, Restricted, or Transferred)
- Committed to **generating positive impact for society with safe and sustainable chemistry**



## Governance progress

- Establishing the combined **Group Innovation & Sustainability (GIS)**
- Implementing **new governance tools** to steer CO<sub>2</sub> reduction
- Ensuring the highest compliance standards with an updated **Code of Ethics**



## UN SDGs with highest impact




<sup>1</sup> Science-Based Target initiative (SBTi); <sup>2</sup> versus baseline 2019

# Ambitious Emission Reduction Targets in a Growth Environment – Roadmaps toward Targets Defined and in Execution



## Reducing our carbon footprint...


40 % reduction in Scope 1&2 emissions



- The production volume increase (+8 %) outpaced the Scope 1 & 2 GHG emission increase of +3 % from 2019 to 2021. This development was driven by an accelerated transition to renewables, specifically the switch from coal to biofuel at some sites, and a higher share of green electricity purchased
- Accelerated impact of CAPEX projects for GHG reduction to be expected from 2023 onward due to the execution time required
- 2030 target achievement will rely on energy transition (renewables and green electricity) and energy efficiency measures

## ...and the carbon footprint of our raw materials

14 % reduction in Scope 3 emissions




- Scope 3 GHG emissions from purchased goods and services decreased by -1 % compared to 2019, despite a +8 % volume increase
- This reflects the successful execution of Scope 3 roadmap projects. Implementing projects in the pipeline and identifying new reduction opportunities are of high strategic focus across the organization
- 2030 target achievement will rely on broader decarbonization of raw material value chains, including use of alternatives to fossil-based routes (i.e., bio-based) and secondary raw materials (i.e., recycled)

# A Leader in Low Carbon Intensity Today and Tomorrow




**GHG Emissions Intensity**

**Scope 1&2 Emissions vs. Peers**  
tCO<sub>2</sub>e/CHF m 2021 sales




**Scope 3 Emissions vs. Peers**  
tCO<sub>2</sub>e/CHF m 2021 sales




**GHG Emissions Reduction Targets**

**Scope 1&2 Emissions Reduction Target vs. Peers**  
% reduction 2019 – 30



**Scope 3 Emissions Reduction Target vs. Peers**  
% reduction 2019 – 30



<sup>1</sup> reduction of Scope 3, Category 1 emissions

# Adapting Important Social and Governance Aspects to Support the Holistic Sustainability Transformation





## Our Goal: Zero Accidents

Working together with all business units within the framework of the **Avoiding Accidents** program to continually reduce the number of accidents Group-wide

## Safe and Sustainable Chemistry

Committed to **generating positive impact for society with safe and sustainable chemistry**

Examples include **Safebrake® Life**, a hazard label-free brake fluid, contributing to safety in driving and for everybody using it



## Setting up the Right Structures


Bundling expertise for innovative and sustainable solutions by establishing **Group Innovation & Sustainability (GIS)**

## Implementing Effective CO<sub>2</sub> Governance Tools

Integrating CO<sub>2</sub> pricing into CAPEX decision-making and CO<sub>2</sub> performance into short-term incentive plan;  
Stepwise implementation of TCFD recommendations

## Ensuring High Standards

Ensuring the highest compliance standards with an updated **Code of Ethics**



\* Clariant 2021 Continuing Operations; Peers value based on average of Lonza, DSM, AkzoNobel, Umicore, Albemarle, BASF, Evonik, and Clariant

# Clariant is Well Recognized as an Industry Leader by Important ESG Ratings and Rankings status as of December 2021

Index / Ranking / Rating	Clariant score / Percentile rank or range	Status		First year of inclusion
<p>Member of Dow Jones Sustainability Indices Powered by the S&amp;P Global CSA</p>	78 / 98 <sup>th</sup> percentile	DJSI Europe and World Member, Sustainability Yearbook 2021 Member		2012
	81 / 98 <sup>th</sup> percentile	Leader (compared to industry peers)		2016
	AA / Range: AAA to CCC	Second best score		2015
	B- / Top 10 %	“Prime” status and industry leader		2013
	3.7 / 80 <sup>th</sup> percentile	Included in FTSE4 Good Index		2015
	75 / 99 <sup>th</sup> percentile	EcoVadis Platinum Award		2012
	60 / 100 – “advanced”	Included in Ethibel and Euronext indices		2014
	Climate: B- / Range: A to D- Water: B- / Range: A to D-	Below average compared to global Below average compared to global		2013

# The Executive Committee



**Conrad Keijzer**  
Chief Executive Officer

**Responsibilities:**

Group Auditing (together with Chairman of the Audit Committee), Group Communications, Group Compliance, Group Human Resources, and Group Legal



**Hans Bohnen**  
Executive Vice President &  
Chief Operating Officer

**Responsibilities:**

Business Line Biofuels & Derivatives, Business Units Catalysts and Industrial & Consumer Specialties, Group Operational Excellence, Group Procurement Services, and the regions Latin America and North America



**Bernd Hoegemann**  
Executive Vice President &  
Chief Transformation Officer

**Responsibilities:**

Business Units Additives, Functional Minerals, and Oil and Mining Services, as well as Corporate Planning & Strategy, Group Innovation & Sustainability, Project Clariant 2021, and the region China and Asia-Pacific



**Stephan Lynen**  
Executive Vice President &  
Chief Financial Officer

**Responsibilities:**

Corporate Accounting, Corporate Controlling, Corporate Mergers & Acquisitions, Corporate Tax, Corporate Treasury, Global Business Services, Group Finance Services, Group Investor Relations, Group Information Technology, and the regions Europe, Middle East & Africa



# Calendar of Upcoming Corporate Events

---

24 June 2022

Annual General Meeting

---

28 July 2022

Second Quarter / First Half Year 2022 Reporting

---

27 October 2022

Third Quarter / Nine Month 2022 Reporting

---

01 March 2023

Fourth Quarter / Full Year 2022 Reporting

---





# IR Contacts

---

**Andreas Schwarzwälder**  
Head of Investor Relations

Phone: +41 61 469 63 73

Email: [investor-relations@clariant.com](mailto:investor-relations@clariant.com)

---

**Maria Ivek**  
Senior Investor Relations Officer

---

**Alexander Kamb**  
Investor Relations Officer

---